Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Other Non-Current Assets (2019 - 2026)

Inspire Medical Systems' Other Non-Current Assets history spans 8 years, with the latest figure at $17.2 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 41.95% to $17.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.2 million, a 41.95% increase, with the full-year FY2025 number at $17.3 million, up 52.37% from a year prior.
  • Other Non-Current Assets hit $17.2 million in Q1 2026 for Inspire Medical Systems, roughly flat from $17.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for INSP hit a ceiling of $17.3 million in Q3 2025 and a floor of $454000.0 in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $11.5 million across 5 years, with a median of $11.3 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: surged 5152.45% in 2022 and later dropped 14.72% in 2025.
  • Tracing INSP's Other Non-Current Assets over 5 years: stood at $10.7 million in 2022, then grew by 5.25% to $11.3 million in 2023, then increased by 0.46% to $11.3 million in 2024, then surged by 52.37% to $17.3 million in 2025, then decreased by 0.08% to $17.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for INSP at $17.2 million in Q1 2026, $17.3 million in Q4 2025, and $17.3 million in Q3 2025.